How the CDC can Influence the Medical Innovation Pipeline
June 24, 2026
When To Hold And When To Sell Or License a Medical Patent
July 1, 2026
Medical Patents Broker Inc.
By Kenneth Pearce, President
On the FDA Autobahn, the right lane is for slow trucks that can be moving trash and an occasional gemstone, while the leftmost lane is for the sports car set on autopilot and carrying just the necessary documents and evidence over the finish line.
Some examples of business models are:
The Dump Truck Model
The owner met a guy who knows a guy who knows a director at Company 123. Does this ever come to pass? In movie plots yes, but in the real world, it’s usually a mere vapor in time. Serendipitous circumstances rarely alter the finish line. Without any third-party vetting, the probability of transferring the medical patent from the truck to the patient is very slim.
Right Lane: Unless a miracle occurs, too many dead weights are holding it back—it remains in the right lane until it’s too late to pass.
The Sports Car Model (Different Lanes, Different Momentums)
1. Universities & CROs: A University and its Clinical Research Organizations (CROs) have a symbiotic partnership, and the combination moves the technology toward the finish line.
Middle Lane: Equipped with an adequate engine to pass to the next lane when the opportunity arises.
2. Manufacturer Acquisitions or Licenses: A manufacturer acquires or licenses patent rights for the medical invention owned by a company or an individual inventor. This can be a good fit for both parties when the manufacturer has experience moving the technology toward the patient.
Middle Lane: Can shift to sixth gear when needed to transfer the technology.
3. The Phase III Company with FDA Approval: In the medical technology business, this is the golden key that opens doors. Management smiles, and soon the patient can too.
The Leftmost Passing Lane: Forget the gears, the sports car just grew wings.
The General Rule
The more patent term remaining and the closer the technology is to the patient, the more monetary value the patent will have. Every day lost in waiting to change the patent’s circumstances reduces potential profit.
Before any medical patent is listed on MPB’s marketplace, it is scrutinized by MPB’s trade secret metrics. Many requests to list are rejected.
With the exception of a Phase III company that already holds FDA approval, MPB provides a platform for vehicles to switch to a faster lane via its public and private portals. Straight-up sales, hybrids, and straight-up licenses of the IP are the gears of progress toward the patient. For MPB’s clients, it can lead to a clean exit or a highly lucrative, long-term license. Both the seller and the licensee move forward with an agreed-upon price point.
The President’s Viewpoint
MPB’s marketplace provides the ability to change to a faster lane of the FDA Autobahn. With an agreed price point, the rest of the negotiations become easier.
One party enters one of the fast lanes, and the other party can drive a little slower until the next medical patent comes along. There are inventors, and then there are medical inventors—many of whom never seem to rest for long.
